CareDx, Inc (CDNA)
NASDAQ: CDNA · Real-Time Price · USD
12.13
-0.33 (-2.65%)
At close: Aug 13, 2025, 4:00 PM
12.19
+0.06 (0.48%)
After-hours: Aug 13, 2025, 5:44 PM EDT
CareDx Revenue
CareDx had revenue of $86.68M in the quarter ending June 30, 2025, a decrease of -6.06%. This brings the company's revenue in the last twelve months to $340.83M, up 14.72% year-over-year. In the year 2024, CareDx had annual revenue of $333.79M with 19.07% growth.
Revenue (ttm)
$340.83M
Revenue Growth
+14.72%
P/S Ratio
1.98
Revenue / Employee
$524,348
Employees
650
Market Cap
645.64M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 333.79M | 53.46M | 19.07% |
Dec 31, 2023 | 280.32M | -41.47M | -12.89% |
Dec 31, 2022 | 321.79M | 25.40M | 8.57% |
Dec 31, 2021 | 296.40M | 104.20M | 54.22% |
Dec 31, 2020 | 192.19M | 65.13M | 51.25% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CDNA News
- 6 days ago - CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - CareDx Announces Appointment of Nathan Smith as Chief Financial Officer - Business Wire
- 7 days ago - CareDx Announces Second Quarter 2025 Financial Results - Business Wire
- 7 days ago - CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation - Business Wire
- 13 days ago - CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress - Business Wire
- 21 days ago - CareDx to Report Second Quarter 2025 Financial Results - Business Wire
- 26 days ago - CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection - Business Wire
- 2 months ago - CareDx: The Transplant Diagnostics Leader, But Challenges Will Increase On The Road Ahead - Seeking Alpha